Growth hormone-releasing hormone antagonists inhibited human ovarian cancer growth through multiple mechanisms — direct antiproliferative, reduced IGF-1 signaling, and apoptosis induction — adding ovarian cancer to GHRH antagonist targets.
Key findingGrowth hormone-releasing hormone antagonists inhibited human ovarian cancer growth through multiple mechanisms — direct antiproliferative, reduced IGF
What the researchers found
Growth hormone-releasing hormone antagonists inhibited human ovarian cancer growth through multiple mechanisms — direct antiproliferative, reduced IGF-1 signaling, and apoptosis induction — adding ovarian cancer to GHRH antagonist targets.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 43(11), 816-20
Citation
Papadia, A; Schally, A V; Halmos, G; Varga, J L; Seitz, S; Buchholz, S; Rick, F; Zarandi, M; Bellyei, S; Treszl, A; Szalontay, L; Lucci, J A. (2011). Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 43(11), 816-20. https://doi.org/10.1055/s-0031-1287766